Advertisement


Jennifer Woyach, MD, on CLL/SLL: Pirtobrutinib vs Ibrutinib in Treatment-Naive and Relapsed/Refractory Disease

ASH 2025

Advertisement

Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses results from the first head-to-head comparison of pirtobrutinib vs ibrutinib in treatment-naive patients and patients with covalent Bruton tyrosine kinase inhibitornaive relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (Abstract 683). 



Related Videos

Multiple Myeloma

Krina Patel, MD, MSc, on Anitocabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Krina Patel, MD, MSc, of The University of Texas MD Anderson Cancer Center, provides updated results from the fully enrolled, ongoing iMMagine-1 phase II registrational trial of anitocabtagene autoleucel, an autologous anti-BCMA CAR T-cell therapy with a novel D-domain binder. The agent is under development for patients with relapsed and/or refractory multiple myeloma (Abstract 256). 

Myelodysplastic Syndromes

Valeria Santini, MD, on Imetelstat for Lower-Risk MDS: Long-Term Outcomes From the IMerge Trial

The telomerase inhibitor imetelstat was approved for the treatment of certain patients with lower-risk myelodysplastic syndromes (MDS) based on the results of the phase III IMerge trial. Valeria Santini, MD, of the University of Florence, provides updates on secondary endpoints, including overall and progression-free survival; progression to acute myeloid leukemia; safety; and long-term outcomes by subgroups of interest in IMerge, as well as ad hoc outcomes, including overall survival by response (Abstract 2074). 

Leukemia

Anand Patel, MD, on Ph-Positive ALL: TKI Plus Inotuzumab Ozogamicin–Based Therapy

Anand Patel, MD, of the University of Chicago, discusses results from a phase II trial that showed tyrosine kinase inhibitor plus inotuzumab ozogamicinbased therapy resulted in major molecular response in patients newly diagnosed with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) (Abstract 441). 

Leukemia

Nitin Jain, MD, on a Triplet Regimen for Richter Transformation

Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, reviews findings from a phase II trial of pirtobrutinib, venetoclax, and obinutuzumab for patients with Richter transformation (Abstract 89). 

Myelodysplastic Syndromes

Amer Zeidan, MBBS, on Lower-Risk MDS: Treatment-Emergent Cytopenias and Clinical Response

Amer Zeidan, MBBS, of Yale School of Medicine, discusses findings from an analysis of the IMerge trial, which explored the possible association between imetelstat-related cytopenias and hemoglobin increasea measure linked to red blood cell transfusion independence achievement—in patients with lower-risk myelodysplastic syndromes (MDS) (Abstract 490). 

Advertisement

Advertisement




Advertisement